Jérôme Lemonnier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jérôme Lemonnier has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Suzette Delaloge
Department of Cancer Medicine, Gustave Roussy, Villejuif, France
15 shared publications - Thomas Bachelot
Medical Oncology Department, Centre Léon Bérard, Lyon, France
13 shared publications - Florence Dalenc
Oncopole Claudius Regaud, IUCT, Toulouse, France
12 shared publications - Etienne Brain
Department of Medical Oncology, Institut Curie, Saint-Cloud, France
11 shared publications - Francois P. Duhoux
Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, and Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium
11 shared publications - Adrien Buisson
Department of Biopathology Centre Léon Bérard Lyon France
10 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in The Breast
- Vol. 89
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
- 7 August 2026
- Published by Elsevier in The Breast
- Vol. 89
Open AccessPrediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- 21 April 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (8) , 1093-1105
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
- Open Access
- 1 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116152
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial
- 1 December 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 233, 116152
Open AccessCombination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details of genetic counselling recommended after NGS analysis
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Details of genetic counselling recommended after NGS analysis
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Protocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessProtocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Centralized panel-NGS and Tumor PD-L1 expression analysis
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Centralized panel-NGS and Tumor PD-L1 expression analysis
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Representativeness of Study Participants
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Representativeness of Study Participants
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics in the previously documented germline BRCA mutated population
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics in the previously documented germline BRCA mutated population
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics (evaluable population)
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Baseline patient and tumor characteristics (evaluable population)